<DOC>
	<DOCNO>NCT00158561</DOCNO>
	<brief_summary>To determine whether two cheap antifolates ( chlorproguanil-dapsone sulfadoxine-pyrimethamine ) work falciparum malaria region sufficiently effective vivax malaria deploy area diagnosis poor burden malaria high , randomise control trial three drug undertaken compare efficacy treat malaria .</brief_summary>
	<brief_title>Chlorproguanil/Dapsone Compared With Chloroquine SP Vivax Malaria</brief_title>
	<detailed_description>Objectives : Primary : To evaluate comparative efficacy chlorproguanil / dapsone sulfadoxine-pyrimethamine treatment vivax malaria Pakistan eastern Afghanistan . Secondary : - To compare efficacy chlorproguanil-dapsone sulfadoxine-pyrimethamine chloroquine - To evaluate safety profile chlorproguanil / dapsone south Asians region use treatment vivax malaria . - To evaluate effect chlorproguanil / dapsone gametocyte clearance rate . - To evaluate effect chlorproguanil / dapsone subsequent relapse due vivax malaria . Study Population : 750 P.vivax positive individual recruit Malaria Reference Centre Jalalabad , Afghanistan health facility Afghan refugee camp North West Frontier Province ( NWFP ) , Pakistan supervise HealthNet International Efficacy Parameters : Primary Efficacy Variable : â€¢ Day 14 slide clearance rate ( complete clearance parasite ) , assessed microscopist blind treatment allocation . Slides double read . Secondary Efficacy Variables - Day 28 slide clearance rate define number treat patient clearance parasitaemia within 14 day start treatment , without subsequent recrudescence day 28 . - Day 14 clinical failure rate ( presence symptom malaria presence parasitaemia ) . - Day 28 clinical failure rate . - Adverse event . - Haemoglobin level increase least 1g/dl day 14 . - Clearance gametocytaemia day 3 , 7 , 14 . - Number subsequent malaria episode next 6 month . It assume population treatment arm equally likely re-infected time scale . Therefore measurable difference number subsequent episode treatment arm due relapse . - In G6PD deficient patient change mean haemoglobin . Safety Parameters : Adverse event laboratory finding monitor patient . Regular haemoglobin identify haemolysis . Study design : Recruitment administration : Recruitment administration treatment directly observe trial coordinator trial pharmacist , and/or health unit clinician . Dosing Schedules : Chlorproguanil-dapsone ( Lapdap ) : ( target dose 2.0 2.5 mg/kg respectively ) daily 3 day . Sulfadoxine - pyrimethamine ( SP ) : ( target dose 1.25 25.0 mg/kg respectively ) . Chloroquine ( CQ ) : ( target dose 25mg/kg ) daily 3 day . Follow : Patients return clinic day 0 , 1 , 2 , 3 , 7 , 14 , 21 28 supervise dosing , thick thin smear , blood spot filter paper , update clinical record form , determination haemoglobin , full blood cell count , liver function test , determination adverse event concomitant medication detail , appropriate .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Chlorproguanil</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>1 . Presentation BHU clinic probable clinical malaria . 2 . Infection P. vivax , confirm microscopy . 3 . Age 3 year old ( restriction upper age limit ) . 4 . Written witnessed verbal consent obtain patient patient parent guardian . 5 . Married woman child bear age confirm nonpregnant outset willing remain thus duration study . 6 . Willingness comply requirement protocol particularly provide venous thumb prick blood sample . 7 . Available follow duration study le 6 month . 8 . Willingness report BHU clinic feel unwell 6 month follow completion ( i.e . 7 month enrolment date ) . NB patient recruit 7 month end study period . 9 . Availability G6PD status willingness test admission . 1 . General condition require hospital admission . 2 . Evidence concomitant infection likely mask treatment response time presentation . 3 . Presence underlying disease compromise diagnosis evaluation response study medication . 4 . History allergy sulphonamides , dapsone chloroquine hypersensitivity biguanides ( eg proguanil , chlorproguanil ) sulphones ( eg frusemide , thiazide , acetazolamide , sulphonylureas ) tablet content . 5 . Known methaemoglobin reductase deficiency haemoglobin M. 6 . Treatment within past twentyeight day sulfadoxine/pyrimethamine ( Fansidar ) , sulfalene/pyrimethamine ( Metakelfin ) , mefloquinesulfadoxinepyrimethamine ( Fansimef ) ; 21days mefloquine , 7days amodiaquine , chloroquine , halofantrine , quinine ( full course ) , primaquine , atovaquone proguanil , artemisinin derivative , coartemether , trimethoprim , chloramphenicol , erythromycin , tetracycline clindamycin . 7 . Visible jaundice . 8 . Use investigational drug within 30 day 5 halflives whichever longer . 9 . Severe anaemia ( Hb &lt; 7 g/dl ) . 10 . Other specie malaria see . 11 . Pregnancy , assessed pregnancy test marry woman childbearing age ( age 14 50 ) .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>vivax</keyword>
	<keyword>treatment</keyword>
	<keyword>Asia</keyword>
</DOC>